Ignite Creation Date:
2024-05-06 @ 2:13 AM
Last Modification Date:
2024-10-26 @ 11:15 AM
Study NCT ID:
NCT01998126
Status:
COMPLETED
Last Update Posted:
2018-04-02
First Post:
2013-07-11
Brief Title:
Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer
Sponsor:
University of Utah
Organization:
University of Utah
Organization Data
Organization:
University of Utah
Class:
OTHER
Study ID:
HCI66705
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
University of Utah
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Bristol-Myers Squibb | INDUSTRY |